TABLE 2.
Overview of clinical trials targeting the CCL2‐CCR2 axis
| Target | Drug name | Conditions | Phase | Status | Trial number |
|---|---|---|---|---|---|
| CCL2 | Carlumab | Patients with metastatic castrate‐resistant prostate cancer. | Phase II | Completed | NCT00992186 |
| Combination with chemotherapy in patients with solid tumours. | Phase I | Completed | NCT01204996 | ||
| Patients with solid tumours. | Phase I | Completed | NCT00537368 | ||
| CCR2 | MLN1202 | Cancer patients with bone metastases. | Phase Ⅱ | Completed | NCT01015560 |
| CCR2/CCR5 | BMS‐813160 | With or without GVAX for locally advanced pancreatic ductal adenocarcinomas. | Phase Ⅰ/Ⅱ | Recruiting | NCT03767582 |
| Combination with Nivolumab, Gemcitabine and Nab‐paclitaxel in borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC). | Phase Ⅰ/Ⅱ | Recruiting | NCT03496662 | ||
| Combination with chemotherapy or Nivolumab in patients with pancreatic cancer. | Phase Ⅰ/Ⅱ | Not recruiting | NCT03184870 | ||
| Combination treatments in patients with advanced renal cell carcinoma. | Phase Ⅱ | Recruiting | NCT02996110 | ||
| Combination treatments in patients with hepatocellular carcinoma. | Phase Ⅱ | Recruiting | NCT04123379 | ||
| CCR2 | CCX872‐B | Patients with pancreatic adenocarcinoma. | Phase Ⅰ | Not recruiting | NCT02345408 |
| Preoperative stereotactic body radiation therapy for pancreatic adenocarcinoma. | Phase Ⅰ/Ⅱ | Withdrawn | NCT03778879 | ||
| CCR2 | PF‐04136309 | Patients with borderline resectable and locally advanced pancreatic adenocarcinoma. | Phase Ⅰ | Completed | NCT01413022 |
| Combination with Gem/Nab‐P in first‐line metastatic pancreatic patients. | Phase Ⅱ | Terminated | NCT02732938 |